ASRT
$12.50
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States.
Intraday
Recent News
Assertio Holdings Inc (ASRT) Q4 2025 Earnings Call Highlights: Navigating Challenges with ...
Despite a challenging quarter, Assertio Holdings Inc (ASRT) focuses on strategic growth opportunities and improved margins to drive future success.
Assertio Holdings, Inc. Q4 2025 Earnings Call Summary
Moby summary of Assertio Holdings, Inc.'s Q4 2025 earnings call
Assertio Q4 Earnings Call Highlights
Assertio (NASDAQ:ASRT) executives used the company’s fourth-quarter and full-year 2025 earnings call to outline a sharper strategic focus on growing its oncology franchise around Rolvedon, while becoming more selective on business development following what leadership described as a less capital-eff
Assertio (ASRT) Q4 2025 Earnings Call Transcript
Good afternoon, and thank you all for joining us today to discuss Assertio Holdings, Inc.'s fourth quarter 2025 financial results and business update. Please note that during this call, management will make projections and other forward-looking statements regarding our future performance. Such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties, including those noted in this afternoon's press release as well as Assertio Holdings, Inc.'s filings with the SEC.
Assertio (ASRT) Reports Q4 Loss, Beats Revenue Estimates
Assertio (ASRT) delivered earnings and revenue surprises of +39.02% and +185.10%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?